Skye Bioscience, Inc. - SKYED STOCK NEWS

Welcome to our dedicated page for Skye Bioscience news (Ticker: skyed), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.

Skye Bioscience, Inc. (SKYED) is a clinical-stage biopharmaceutical company advancing cannabinoid-derived therapeutics for ocular and metabolic diseases. This page provides official updates on regulatory milestones, clinical trial progress, and research developments for investors and industry observers.

Access consolidated information about SBI-100 Ophthalmic Emulsion glaucoma trials and nimacimab cardio-metabolic studies, including DEA-authorized multi-site research initiatives. Track Phase 2 enrollment timelines and therapeutic pipeline updates through verified press releases and regulatory filings.

All content undergoes strict verification to ensure accuracy regarding trial protocols, safety data disclosures, and regulatory compliance. Bookmark this page for real-time updates on Skye Bioscience's pioneering work in CB1 receptor modulation therapies.

10/19/2023 07:00 AM

News

Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Rhea-AI Summary

Skye Bioscience to host virtual Investor Day and release Phase 1 clinical data

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.21%

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

Rhea-AI Summary

Skye Bioscience announces patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist. DEA authorizes three clinical trial sites for Phase 2a study of SBI-100 OE. Safety data for Phase 1 study to be reported in October. Financing fully funded Phase 2a study. Positive outcome critical for development of SBI-100 OE. Interim analysis expected in Q1 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.76%

Skye Bioscience Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

Skye Bioscience, Inc. (OTCQB: SKYED) will be presenting a corporate overview at the 2023 Cantor Global Healthcare Conference and the 16th Annual LD Micro Main Event. Punit Dhillon, Chairman and CEO, will be available for 1:1 meetings with investors during the conference. Interested parties can register to watch the presentation virtually. Tu Diep, Chief Development Officer, will also be presenting at the LD Micro Main Event and will be available for 1:1 meetings with investors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.95%